Pre-Made Dalcinonacog Alfa Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Dalcinonacog alfa (DalcA) is being developed for the treatment of Hemophilia B. DalcA was developed using a rational design approach with three amino acid substitutions in two loops (within the Coagulation factor IX (FIX) protein to significantly enhance affinity to the cofactor VIII and stabilize activated FIX (FIXa).